Maze Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)-- Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that company management will participate in upcoming investor conferences in February and March 2024. Details of the events are as follows:
-
Evercore ISI 2024 Emerging Biotech Conference
- Management will present during the virtual conference on Thursday, February 29, 2024 from 3:25-3:55 p.m. ET
- The webcast will be available live and on demand here.
-
Cowen Healthcare Conference 2024
- Management will participate in one-on-one investor meetings on Monday, March 4, 2024
-
Leerink Partners Global Biopharma Conference
- Management will participate in one-on-one investor meetings on Wednesday, March 13, 2024
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage insights from genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226227699/en/
Jillian Connell, Maze Therapeutics
[email protected]
(650) 850-5080
Media:
Dan Budwick, 1AB
[email protected]
Source: Maze Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aster Guardians Global Nursing Award 2026 Names Agimol Pradeep From United Kingdom Winner of USD 250,000 Prize
- Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
- Calvin Klein Collection by Veronica Leoni Spring 2027 Runway Show Presented in New York City
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share